JP2006514607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514607A5 JP2006514607A5 JP2004523679A JP2004523679A JP2006514607A5 JP 2006514607 A5 JP2006514607 A5 JP 2006514607A5 JP 2004523679 A JP2004523679 A JP 2004523679A JP 2004523679 A JP2004523679 A JP 2004523679A JP 2006514607 A5 JP2006514607 A5 JP 2006514607A5
- Authority
- JP
- Japan
- Prior art keywords
- absent
- ala
- arg
- lys
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 31
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 21
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims 18
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 239000012503 blood component Substances 0.000 claims 10
- 239000003937 drug carrier Substances 0.000 claims 9
- -1 methylamino, hydroxyethyl Chemical group 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 6
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 5
- 206010019280 Heart failures Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- 230000000903 blocking effect Effects 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- JJVJPJWQXDQCEI-UHFFFAOYSA-N ethenylhydrazine Chemical group NNC=C JJVJPJWQXDQCEI-UHFFFAOYSA-N 0.000 claims 3
- 125000000524 functional group Chemical group 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 229940124530 sulfonamide Drugs 0.000 claims 3
- 150000003456 sulfonamides Chemical class 0.000 claims 3
- 102000004506 Blood Proteins Human genes 0.000 claims 2
- 108010017384 Blood Proteins Proteins 0.000 claims 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 2
- 108020001621 Natriuretic Peptide Proteins 0.000 claims 2
- 102000004571 Natriuretic peptide Human genes 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 2
- 239000000692 natriuretic peptide Substances 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical group O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40019902P | 2002-07-31 | 2002-07-31 | |
| US40041302P | 2002-07-31 | 2002-07-31 | |
| PCT/CA2003/001097 WO2004011498A2 (en) | 2002-07-31 | 2003-07-29 | Long lasting natriuretic peptide derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009273992A Division JP2010047614A (ja) | 2002-07-31 | 2009-12-01 | 長時間持続性ナトリウム排泄増加性ペプチド誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006514607A JP2006514607A (ja) | 2006-05-11 |
| JP2006514607A5 true JP2006514607A5 (https=) | 2006-09-07 |
Family
ID=31191354
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004523679A Pending JP2006514607A (ja) | 2002-07-31 | 2003-07-29 | 長時間持続性ナトリウム排泄増加性ペプチド誘導体 |
| JP2009273992A Pending JP2010047614A (ja) | 2002-07-31 | 2009-12-01 | 長時間持続性ナトリウム排泄増加性ペプチド誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009273992A Pending JP2010047614A (ja) | 2002-07-31 | 2009-12-01 | 長時間持続性ナトリウム排泄増加性ペプチド誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1530588A2 (https=) |
| JP (2) | JP2006514607A (https=) |
| AU (1) | AU2003246500A1 (https=) |
| CA (1) | CA2488348A1 (https=) |
| WO (1) | WO2004011498A2 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| DK1360202T3 (da) | 2001-02-16 | 2008-09-22 | Conjuchem Biotechnologies Inc | Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser |
| WO2004022003A2 (en) | 2002-09-06 | 2004-03-18 | University Of South Florida | Materials and methods for treatment of allergic diseases |
| US7648962B2 (en) | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
| WO2004047871A2 (en) | 2002-11-26 | 2004-06-10 | Nobex Corporation | Modified naturetic compounds, conjugates, and uses thereof |
| AU2005227870A1 (en) | 2004-02-17 | 2005-10-13 | University Of South Florida | Materials and methods for treatment of inflammatory and cell proliferation disorders |
| CA2559228C (en) | 2004-04-21 | 2016-06-21 | Enobia Pharma Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| WO2006005140A2 (en) | 2004-07-15 | 2006-01-19 | The University Of Queensland | Proteinaceous compounds and uses therefor |
| ES2363738T3 (es) * | 2005-03-07 | 2011-08-12 | Mondobiotech Ag | Formulación de aviptadil. |
| WO2006108686A2 (en) * | 2005-04-14 | 2006-10-19 | Aic | Bnp agonists |
| US20080227713A1 (en) * | 2005-10-03 | 2008-09-18 | Protter Andrew A | Oxidized Human Bnp |
| WO2007127487A2 (en) | 2006-04-28 | 2007-11-08 | University Of South Florida | Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor |
| JP5010913B2 (ja) * | 2006-12-31 | 2012-08-29 | 寿子 小出 | 心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法 |
| KR20080098216A (ko) * | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
| US20100310561A1 (en) * | 2007-06-06 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Natriuretic fusion proteins |
| AP2009005091A0 (en) * | 2007-07-06 | 2009-12-31 | Theratechnologies Inc | Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (ALPHA-MSH) and atrial natriuretic protein (ANP) and uses in hypertension andacute kidney injury |
| DE102010032482A1 (de) | 2010-07-28 | 2012-02-02 | Justus-Liebig-Universität Giessen | Stoffe zur Beeinflussung der natriuretischen Peptid-Rezeptoren A und B und deren Verwendung |
| WO2012013597A1 (de) | 2010-07-28 | 2012-02-02 | Justus-Liebig-Universität Giessen | Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren |
| WO2012088608A1 (en) | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
| CN103402534B (zh) * | 2011-02-23 | 2016-10-12 | 麦德林制药私人有限公司 | 用于治疗充血性心力衰竭的治疗方法 |
| US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
| CN102286092B (zh) | 2011-09-14 | 2014-01-01 | 深圳翰宇药业股份有限公司 | 利拉鲁肽的固相合成方法 |
| AU2013263349B2 (en) | 2012-05-17 | 2016-09-08 | Extend Biosciences, Inc | Carriers for improved drug delivery |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| MX389350B (es) | 2014-12-05 | 2025-03-19 | Alexion Pharma Inc | Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones. |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| CA2986086A1 (en) * | 2015-05-29 | 2016-12-08 | Igisu Co., Ltd. | Cyclyc peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide |
| CN108350440A (zh) | 2015-08-17 | 2018-07-31 | 阿雷克森制药公司 | 碱性磷酸酯的制造 |
| JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定 |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| JP7613826B2 (ja) | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| EP3600383A4 (en) | 2017-03-31 | 2020-10-28 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| CA3161266A1 (en) | 2019-12-09 | 2021-06-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| AU2021337652B2 (en) | 2020-09-04 | 2025-01-30 | Alexion Pharmaceuticals, Inc. | Methods for treating bone mineralization disorders |
| BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
| KR20250075704A (ko) | 2022-09-30 | 2025-05-28 | 익스텐드 바이오사이언시즈, 인크. | 장기-지속형 부갑상선 호르몬 |
| WO2024086680A2 (en) | 2022-10-21 | 2024-04-25 | Eli Lilly And Company | Long-acting natriuretic peptides and uses thereof |
| CN116284329B (zh) * | 2023-04-28 | 2023-12-08 | 成都奥达生物科技有限公司 | 一种长效利钠肽化合物 |
| CN121717878A (zh) * | 2024-12-02 | 2026-03-24 | 中山大学 | 一种用于npr-b靶向的超长效多肽及其在骨骼系统病症中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI872959A7 (fi) * | 1985-11-05 | 1987-07-03 | California Biotechnology Inc | Natriureettisen vaikutuksen omaavien sydämen eteispeptidien analogeja . |
| JP3042782B2 (ja) * | 1985-11-05 | 2000-05-22 | サイオス インコーポレイテッド | 心房性ナトリウム尿排泄亢進ペプチド類似化合物 |
| GR1001018B (el) * | 1989-05-24 | 1993-03-31 | Abbott Lab | Μεθοδος παρασκευης προδρομικων πεπτικων παραγωγων. |
| JP4209086B2 (ja) * | 1999-05-17 | 2009-01-14 | コンジュケム バイオテクノロジーズ インコーポレイテッド | 長期持続性抗新脈管形成ペプチド |
| CA2373680C (en) * | 1999-05-17 | 2008-07-29 | Conjuchem Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| WO2001017568A2 (en) * | 1999-09-07 | 2001-03-15 | Conjuchem, Inc. | Bioconjugation in vivo to pulmonary or blood components |
-
2003
- 2003-07-29 JP JP2004523679A patent/JP2006514607A/ja active Pending
- 2003-07-29 EP EP03771007A patent/EP1530588A2/en not_active Ceased
- 2003-07-29 AU AU2003246500A patent/AU2003246500A1/en not_active Abandoned
- 2003-07-29 CA CA002488348A patent/CA2488348A1/en not_active Abandoned
- 2003-07-29 WO PCT/CA2003/001097 patent/WO2004011498A2/en not_active Ceased
-
2009
- 2009-12-01 JP JP2009273992A patent/JP2010047614A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006514607A5 (https=) | ||
| JP6229038B2 (ja) | 修飾された血管作動性腸管ペプチド | |
| JP4175668B2 (ja) | Ｏｂ融合タンパク質組成物および方法 | |
| AU2009280021B2 (en) | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal | |
| JP2020502051A5 (https=) | ||
| AU672589B2 (en) | Novel amylin antagonist peptides and uses therefor | |
| JP2004520395A5 (https=) | ||
| KR100905380B1 (ko) | 신경펩타이드-2 수용체(ｙ２ｒ) 작용물질 활성을 갖는펩타이드 | |
| AU638423B2 (en) | Therapeutic peptides | |
| JP2020007338A (ja) | グルカゴン及びｇｌｐ−１共アゴニスト化合物 | |
| JP2012530145A5 (https=) | ||
| CN102532301B (zh) | 一类新型的Exendin-4类似物及其制备方法 | |
| JP2011511753A5 (https=) | ||
| CA2488348A1 (en) | Long lasting natriuretic peptide derivatives | |
| JP2023541798A (ja) | Ｃｒｆ２受容体アゴニスト及び治療におけるその使用 | |
| KR20110125235A (ko) | 뉴로펩타이드 ｙ 수용체 결합성 화합물을 포함하는 세포독성 접합체 | |
| TW202317604A (zh) | 用於治療遺傳性血鐵沉積症之鐵調素模擬物 | |
| ES2360598T3 (es) | Receptores de linfocitos t que se unen especificamente a vygfvracl-hla-a24. | |
| JP6046060B2 (ja) | エイズの治療のための、ポリアニオン性ポリペプチドと結合しているｃｄ４受容体由来ペプチドを含んでなる新規コンジュゲート分子 | |
| JPH01131197A (ja) | Ａｎｆ活性を有するペプチド類 | |
| JP2003500341A5 (https=) | ||
| JP2024504136A5 (https=) | ||
| JP2005082489A6 (ja) | 新規な摂食促進ペプチド、新規な成長ホルモン分泌促進ペプチド | |
| TW202231655A (zh) | 用於診斷及治療之改良的膽囊收縮素-2受體(cck2r)標靶 | |
| CN117480176A (zh) | 用于治疗遗传性血色病的铁调素模拟物 |